What is ARA-290 and how is it derived from erythropoietin?

ARA-290, known generically as cibinetide, is an eleven-amino-acid synthetic peptide copied from one solvent-exposed face of the human hormone erythropoietin, and it is investigational everywhere: no medicines regulator has approved it for any indication. The fragment was built to keep the tissue-protective signalling reported for erythropoietin while leaving behind the red-cell stimulation that carried thrombotic and cardiovascular safety signals in large trials of erythropoiesis-stimulating agents. The evidence base sits mostly at the preclinical level, with a small body of phase 2 human data in narrow neuropathic indications, which is a long way short of an established therapy.

What is the amino acid sequence and molecular structure of ARA-290?

The molecule is a linear undecapeptide, pyroglutamyl-EQLERALNSS, and its shortness is the whole design. Stripped of the glycans and disulfide bonds that hold the parent hormone in its four-helix fold, the fragment behaves in solution as a largely disordered chain, which is why the literature attributes its reported activity to a linear stretch of sequence rather than to a preserved three-dimensional shape. For anyone judging what is actually in a vial, that structural simplicity matters: an unglycosylated eleven-residue chain is fully defined by mass spectrometry and amino acid analysis, unlike a glycoprotein whose identity depends on the process that made it.

• Primary sequence: Pyroglutamyl-EQLERALNSS, a linear undecapeptide containing no cysteine residues.
• Molecular weight: Near 1,257 daltons, roughly one twenty-fourth of glycosylated erythropoietin at about 30 kilodaltons.
• Amino-terminal cap: A cyclized glutamine that removes the free alpha-amino group and blunts aminopeptidase attack.
• Solution conformation: Largely disordered by circular dichroism and modelling, without the tight helical geometry of the folded hormone.

Which region of the erythropoietin molecule does ARA-290 correspond to?

Erythropoietin engages its receptor through two chemically distinct interfaces that let one hormone molecule bridge two receptor chains, and the sequence copied into ARA-290 comes from neither of them. It reproduces the aqueous, solvent-exposed face of helix B, a stretch that points outward into solvent even while the hormone is docked on its receptor. That geographic detail is the design hypothesis in a single line: a face free of receptor duty was proposed to be free to contact something else.

• Parent architecture: Four antiparallel alpha helices, A through D, in the type I cytokine fold.
• Receptor interfaces: A high-affinity site 1 and a lower-affinity site 2, built from residues across helices A and D and the connecting loops.
• Copied region: The aqueous, solvent-exposed face of helix B, contacting neither interface.
• Conservation: Well conserved across mammalian erythropoietins, consistent with cross-species reactivity reported in rodent and other preclinical models.

Why does the peptide lack the erythropoietic activity of the parent hormone?

A non-erythropoietic derivative of erythropoietin sounds like a partial agonist that has been tuned down. The published mechanism describes something blunter: the classical receptor signals only when a single hormone molecule clamps two receptor chains together, and an isolated stretch of helix B surface has neither of the interfaces that clamping requires. The practical consequence is a hard limit rather than a weak effect, since a compound built this way offers nothing in anemia.

1. Bridging: One erythropoietin molecule clamps two receptor chains through its two dissimilar interfaces.
2. Kinase apposition: The associated Janus kinase 2 molecules are brought close enough to transphosphorylate.
3. STAT5 cascade: Downstream signalling drives erythroid progenitor survival and proliferation.
4. Where the fragment stops: The eleven-residue chain carries neither interface and no folded scaffold to present them, so step one never happens.

What receptor does ARA-290 engage, and how does it differ from the classical erythropoietin receptor?

The target described in the literature is not the erythropoietin receptor homodimer but a proposed heteromer pairing an erythropoietin receptor subunit with CD131, the beta common chain shared by the receptors for interleukin-3, interleukin-5, and granulocyte-macrophage colony-stimulating factor. Under that model the complex is largely absent from healthy quiescent tissue and appears on injured or metabolically stressed cells, which would give an agonist a lesion-restricted footprint rather than a systemic one. The model is still a working hypothesis: no high-resolution structure of the proposed complex bound to the peptide has been published, and independent replication of the binding data is thinner than the volume of downstream literature suggests.

What is the regulatory and development status of ARA-290?

No medicines regulator has approved ARA-290 or cibinetide for any indication in any jurisdiction, which places it outside the prescribable pharmacopoeia entirely. The clinical record consists of placebo-controlled phase 2 work in sarcoidosis-associated small fibre neuropathy and in painful diabetic peripheral neuropathy, using patient-reported neuropathic symptom instruments and corneal confocal microscopy nerve fibre measures. Everything circulating outside that sponsor program sits in a grey research-chemical market with none of the assurances a regulated supply chain provides.

What problem was the derivation from erythropoietin intended to solve?

Erythropoietin's tissue-protective effects in animal models were reported through the 1990s and 2000s, and the obstacle to using them was never the biology but the dose. Protective exposures required repeated high dosing at exactly the point when large randomized trials of erythropoiesis-stimulating agents were reporting thrombotic and cardiovascular harm, and because harm and benefit ran through the same receptor, lowering the dose removed both. The fragment is the attempt to cut that knot at the molecular level rather than at the prescription pad.

1. Protective signal: Erythropoietin reduced tissue loss and improved functional recovery in animal models of stroke, spinal cord injury, myocardial ischemia, and peripheral nerve damage.
2. Exposure problem: Reaching those protective levels required repeated high dosing.
3. Class safety data: Large randomized trials in cancer-related anemia and chronic kidney disease reported increased thrombotic events, cardiovascular harm, and worse survival signals in some oncology analyses, reshaping labelling for the class.
4. No dose escape: The harms flow from the same receptor and erythroid biology as the intended effect, so a lower dose cut the protection as well as the risk.
5. The separation bet: A molecule engaging only a tissue-protective receptor would leave hematocrit, blood viscosity, and platelet reactivity untouched.

What is known about the pharmacokinetics and stability of the peptide?

An unmodified undecapeptide with no glycans, no albumin-binding moiety, and no size advantage against renal filtration clears fast, and the reported plasma half-life of a few minutes matches that expectation. The puzzle is what follows, because reported effects in trials persisted for days to weeks after intermittent dosing, far outlasting any measurable drug. The explanation offered in the literature is receptor-driven rather than exposure-driven, which also means that direct evidence the peptide reaches peripheral nerve is inferential, resting on functional and nerve fibre density outcomes rather than measured tissue concentrations.

How does ARA-290 compare with full-length erythropoietin and other engineered derivatives?

Three families of molecule attack the same problem from different directions, and they are variations on one mechanistic hypothesis rather than independent bets, since all are described as acting through the erythropoietin receptor and CD131 heteromer. The modified glycoproteins keep the folded scaffold and disable classical signalling chemically; the peptide discards the scaffold and keeps only the eleven-residue epitope. That choice buys cheap synthesis and a small immunogenic surface at the cost of any circulating persistence.

What alternative names, codes, and identifiers refer to this compound in the scientific literature?

Four labels dominate, and which one a search uses changes what the evidence base looks like. That is not a trivia point: someone trying to judge how much independent human data exists for this molecule can badly underestimate or overestimate it by searching a single term. The naming also hides one real imprecision, since the research-stage sequence and the clinical compound are not chemically identical.

• Cibinetide: The international nonproprietary name, used in later clinical publications and in regulatory documents such as orphan designation records.
• ARA-290: The sponsor development code, the prefix tracing to Araim Pharmaceuticals, and still the most common name in secondary sources.
• Helix B surface peptide (HBSP): The uncapped research sequence, appearing mainly in earlier mechanistic and animal literature.
• Erythropoietin-derived helix B peptide: A descriptive phrase used in some papers with no code attached.

How is the peptide manufactured and formulated?

Manufacture is conventional peptide chemistry rather than biotechnology, and that difference is part of the compound's appeal on paper: no cell line, no glycan characterization, no viral clearance burden, and a product defined by a chemical structure instead of by a process. The impurity profile is the familiar synthetic one, with deletion and truncation sequences, racemized residues, and on storage the deamidation of the several asparagine and glutamine residues this sequence carries. That whole quality picture applies only to material made under pharmaceutical quality systems, which is not a safe assumption for peptide sold outside a regulated supply chain.

1. Chain assembly: Solid-phase peptide synthesis using fluorenylmethyloxycarbonyl protection, built on resin from the carboxyl terminus.
2. Amino-terminal cap: Either a pyroglutamate building block coupled directly, the route preferred for batch-to-batch consistency, or controlled cyclization of a terminal glutamine.
3. Purification: Cleavage from the resin followed by preparative reversed-phase high performance liquid chromatography.
4. Release testing: Identity by mass spectrometry and amino acid analysis, purity and related substances, peptide content, water and residual solvents, counterion content, plus sterility and endotoxin for a parenteral batch.
5. Presentation: Lyophilized powder held cold, reconstituted before parenteral administration.